| Name | Tirofiban hydrochloride monohydrate |
| Description | Tirofiban(MK383) hydrochloride monohydrate is a non-peptide glycoprotein IIb/IIIa antagonist. |
| In vitro | METHODS: HUVEC cells were cultured in 24-well plates. The effect of 0.12, 0.25, 1, and 3 μg/ml Tirofiban（MK383） hydrochloride monohydrate on cell growth was determined using cell counting method. Cells were harvested after 72 h and counted using trypan blue.
RESULTS At a concentration of 0.25 μg/ml, the number of cells in the Tirofiban group increased compared with the group without Tirofiban. Tirofiban can induce the growth of HUVEC cells. [1]
METHODS:HUVEC cells were treated with Tirofiban (1mg/mL) at different time points (0, 1, 2, 3, 4 and 5 hours).
RESULTS After Tirofiban treatment, the amount of VEGF produced by HUVECs gradually increased and reached a peak at 2 hours. [2] |
| In vivo | METHODS: Rats were intravenously injected with Tirofiban（MK383） hydrochloride monohydrate (200 μg/kg). Fifteen minutes later, the left renal pedicle was occluded with a small microvascular forceps, and renal ischemia was induced for 45 minutes. Blood was collected 24 hours after reperfusion, and the left kidney was taken for analysis.
RESULTS Tirofiban can reduce SCR and BUN levels in I/R-injured kidneys, improve renal tissue pathological changes, and reduce ROS generation, cell apoptosis, and leukocyte infiltration. [3]
METHODS: 60 μg/kg Tirofiban was administered as an intravenous bolus injection through the tail vein of rats 30 minutes before reperfusion, and the cardiac function of the rats was observed.
RESULTS Tirofiban improved cardiac function, with lower left ventricular end-systolic blood pressure levels, left ventricular pressure maximum change rates of increase and decrease, heart rate, and left ventricular end-diastolic pressure levels. [4] |
| Storage | keep away from direct sunlight,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (101 mM), Sonication is recommended.
|
| Keywords | VEGF | Tirofiban Hydrochloride | MK-383 Hydrochloride | MK 383 Hydrochloride | L700462 hydrochloride | Integrin | HAEC | GPIIb/IIIa | ADP | ACSs |
| Inhibitors Related | Sodium oleate | Ciclopirox | Chebulinic acid | trans-Aconitic acid | Phlorizin | Ginsenoside Rb1 | Chlorpropamide | Bestatin hydrochloride | Revaprazan hydrochloride | Oleic acid | Esomeprazole Sodium | Trichlormethiazide |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-COVID-19 Compound Library | Anti-Cancer Drug Library |
United States
